Feed BSLN.SW
BS

Basilea Pharmaceutica AG BSLN.SW SIX · Healthcare · Switzerland

CHF 71.00 -1.66% -CHF 1.20

Summary

80 / 100 · Bulios Score

What speaks for it

  • Earnings per share grew by 45% a year over the last 3 years.
  • Out of every 100 CHF of revenue, 17 CHF is left as net profit.
  • It earns 19 CHF a year on every 100 CHF of invested capital.
  • The share price is below the Bulios Fair Price.

What to watch

  • Earnings per share swing sharply from year to year.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Current price CHF 71
P/E today 21.9
Biotechnology industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 21.9 CHF for 1 CHF of yearly profit.

Valuation in detail

Is it growing?

Yes, fast

Revenue (CHF)

Diluted EPS (CHF)

  • Analyst estimate

Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 16% a year. Earnings per share grew by 45% a year over the last 3 years.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Yes

It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy